- Conditions
- Metastatic Breast Cancer, Advanced Breast Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Renal Cell Cancer, Non-Small Cell Lung Cancer, Thyroid Cancer, Advanced/Metastatic Non-Small Cell Lung Cancer, Advanced Gastric Cancer, Gastrointestinal Stromal Tumor, Hepatocellular Carcinoma, Pancreatic Islet Cell Carcinoma, Pancreatic Neuroendocrine Tumor
- Interventions
- sunitinib
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 223 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 15
- States / cities
- Atlanta, Georgia • Maywood, Illinois • Iowa City, Iowa + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 1,028
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Liver and Intrahepatic Bile Duct Carcinoma
- Interventions
- Computed Tomography Perfusion Imaging, Liver Biopsy
- Radiation · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8
- Interventions
- Atezolizumab, Bevacizumab, Biospecimen Collection, Computed Tomography, Durvalumab, Ipilimumab, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography, Questionnaire Administration, Stereotactic Body Radiation Therapy, Tremelimumab
- Biological · Procedure · Other + 1 more
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 226 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 138
- States / cities
- Berkeley, California • Cameron Park, California • Fremont, California + 108 more
- Conditions
- Colorectal Adenocarcinoma, Cholangiocarcinoma, Pancreatic Adenocarcinoma, Hepatocellular Adenocarcinoma, Gastric Adenocarcinoma, Esophageal Adenocarcinoma
- Interventions
- ceritinib
- Drug
- Lead sponsor
- Criterium, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 3 more
- Conditions
- Hepatocellular Cancer
- Interventions
- Sorafenib, radiofrequency ablation
- Drug · Procedure
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Cancer
- Interventions
- CPI-613
- Drug
- Lead sponsor
- Cornerstone Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- Atezolizumab, Bevacizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 668 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Baltimore, Maryland • Detroit, Michigan + 5 more
- Conditions
- Non-small Cell Lung Cancer, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer, Hepatocellular Cancer, Colorectal Cancer
- Interventions
- Study sample collection
- Procedure
- Lead sponsor
- University of Missouri-Columbia
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 620 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2027
- U.S. locations
- 1
- States / cities
- Columbia, Missouri
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- Tetrathiomolybdate
- Drug
- Lead sponsor
- National Center for Research Resources (NCRR)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Hepatocellular Carcinoma, Chemoembolization, Therapeutic
- Interventions
- Ultrasound contrast agent (Contrast-enhanced ultrasound), Logiq E9 Scanner (Contrast-enhanced ultrasound)
- Drug · Device
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 3
- States / cities
- La Jolla, California • Philadelphia, Pennsylvania
- Conditions
- AIDS-Related Non-Hodgkin Lymphoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Hepatocellular Carcinoma, HIV Infection, Kaposi Sarcoma, Locally Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Non-Hodgkin Lymphoma, Recurrent Classic Hodgkin Lymphoma, Recurrent Malignant Neoplasm, Refractory Classic Hodgkin Lymphoma, Refractory Malignant Neoplasm, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Unresectable Melanoma
- Interventions
- Antiretroviral Therapy, Biopsy, Biospecimen Collection, Computed Tomography, Pembrolizumab, Positron Emission Tomography
- Drug · Procedure · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 6 more
- Conditions
- Neoplasms
- Interventions
- TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin
- Drug
- Lead sponsor
- Tesaro, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 463 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 64
- States / cities
- Goodyear, Arizona • Scottsdale, Arizona • Tucson, Arizona + 56 more
- Conditions
- Stage III Hepatocellular Carcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Hepatocellular Carcinoma, Unresectable Intrahepatic Cholangiocarcinoma
- Interventions
- Atezolizumab, Bevacizumab, External Beam Radiation Therapy, Pheresis, Pneumococcal 13-valent Conjugate Vaccine, Therapeutic Autologous Dendritic Cells, Durvalumab, Esophagogastroduodenoscopy, Computed Tomography, Positron Emission Tomography, Magnetic Resonance Imaging, Biopsy Procedure, Biospecimen Collection
- Biological · Radiation · Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2029
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Liver Cancer
- Interventions
- Resveratrol, Placebo
- Dietary Supplement · Drug
- Lead sponsor
- University of Louisville
- Other
- Eligibility
- 21 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Colon Carcinoma, Liver and Intrahepatic Bile Duct Carcinoma, Pancreatic Carcinoma
- Interventions
- Biospecimen Collection, Laboratory Biomarker Analysis, Laboratory Procedure
- Procedure · Other
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- HEPATOCELLULAR CARCINOMA
- Interventions
- Darinaparsin
- Drug
- Lead sponsor
- Alaunos Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 6
- States / cities
- Miami, Florida • Atlanta, Georgia • Boston, Massachusetts + 3 more
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Nivolumab, Relatlimab
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Columbus, Ohio
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Durvalumab, Bevacizumab, Placebo
- Drug · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 150 Years
- Enrollment
- 908 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 31 more
- Conditions
- Liver Cancer
- Interventions
- cisplatin-e therapeutic implant
- Drug
- Lead sponsor
- Matrix Pharmaceutical
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1996
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Rochester, Minnesota
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- Regorafenib(Stivarga, BAY73-4506), Pembrolizumab
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Gainesville, Florida • Tampa, Florida + 2 more
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- Sorafenib (Nexavar, BAY43-9006), Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 602 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 35
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 24 more
- Conditions
- Liver Cancer
- Interventions
- Not listed
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 573 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2024
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Carcinoma, Hepatocellular, Head and Neck Neoplasms, Gastrointestinal Neoplasms
- Interventions
- BI 765049, ezabenlimab
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Los Angeles, California • Orange, California + 9 more
- Conditions
- Liver Cancer, Hepatocellular Carcinoma
- Interventions
- Proton radiation therapy
- Radiation
- Lead sponsor
- Loma Linda University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2009
- U.S. locations
- 1
- States / cities
- Loma Linda, California